arrow

From NeuroLex

Jump to: navigation, search



Resource:ProTECT

Name: Resource:ProTECT
Description: Recently, our team completed an NINDS-funded, Phase IIa double-blinded, placebo-controlled pilot clinical trial that examined the pharmacokinetics, safety, and activity of progesterone, a steroid found to have powerful neuroprotective effects in multiple animal models of brain injury. Our pilot study demonstrated a 50% reduction in death among severe TBI patients and less disability among moderate TBI patients treated with progesterone. Based on these promising results and supportive preclinical data, we are conducting a large, phase III clinical trial (ProTECT III) to definitively assess the safety and efficacy of this treatment for adults with moderate to severe acute TBI. The study is slated to begin August 2008.


WHY Progesterone: Although progresterone is widely considered a "sex steroid", it is also a potent neurosteroid. Progesterone is naturally synthesized in the CNS. A large and growing body of animal studies indicate that early administration of progesterone after TBI reduces cerebral edema, neuronal loss, and behavioral deficits in laboratory animals. Certain properties of progesterone make it an ideal therapeutic candidate. First, in contrast to most drugs tested to date, progesterone rapidly enters the brain and reaches equilibrium with the plasma within an hour of administration. Second, unlike other experimental agents, progesterone has a long history of safe use in humans. Finally, the findings of our pilot clinical trial (presented in the Preliminary Data Section, below) indicate that progesterone has consistent and predictable pharmacokinetic properties, is unlikely to produce harm, and may be efficacious for treating acute TBI in humans.
Other Name(s): ProTECT III - Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment: Phase III Clinical Trial
Abbreviation: ProTECT
Parent Organization: Emory University; Georgia; USA
Supporting Agency: NIH
Resource Type(s): Research forum portal
Resource: Resource
URL: http://em.emory.edu/protect/index.cfm
Id: nlx_143806
PMID: PMID 22033509, 17011666
Keywords: Traumatic brain injury, Progesterone, Clinical trial, Neuroprotection, One Mind TBI
Link to OWL / RDF: Download this content as OWL/RDF

Curation status: Curated

For Resource Owners:

A sitemap will keep your NIF Registry description up-to-date and inform search engines about your resource.

Please login to create the sitemap. (top right)

Learn more about what NIF can do for your resource.
Proudly proclaim your inclusion in NIF by displaying the "Registered with NIF" button on your site.

Notes

This page uses this default form:Resource

Contributors

Aarnaud



bookmark
Facts about Resource:ProTECTRDF feed
AbbrevProTECT  +
CurationStatuscurated  +
DefiningCitationhttp://em.emory.edu/protect/index.cfm  +
DefinitionRecently, our team completed an NINDS-fund Recently, our team completed an NINDS-funded, Phase IIa double-blinded, placebo-controlled pilot clinical trial that examined the pharmacokinetics, safety, and activity of progesterone, a steroid found to have powerful neuroprotective effects in multiple animal models of brain injury. Our pilot study demonstrated a 50% reduction in death among severe TBI patients and less disability among moderate TBI patients treated with progesterone. Based on these promising results and supportive preclinical data, we are conducting a large, phase III clinical trial (ProTECT III) to definitively assess the safety and efficacy of this treatment for adults with moderate to severe acute TBI. The study is slated to begin August 2008.


WHY Progesterone: Although progresterone is widely considered a "sex steroid", it is also a potent neurosteroid. Progesterone is naturally synthesized in the CNS. A large and growing body of animal studies indicate that early administration of progesterone after TBI reduces cerebral edema, neuronal loss, and behavioral deficits in laboratory animals. Certain properties of progesterone make it an ideal therapeutic candidate. First, in contrast to most drugs tested to date, progesterone rapidly enters the brain and reaches equilibrium with the plasma within an hour of administration. Second, unlike other experimental agents, progesterone has a long history of safe use in humans. Finally, the findings of our pilot clinical trial (presented in the Preliminary Data Section, below) indicate that progesterone has consistent and predictable pharmacokinetic properties, is unlikely to produce harm, and may be efficacious for treating acute TBI in humans.
icacious for treating acute TBI in humans.
ExampleImageProTECT.PNG  +
Has default formThis property is a special property in this wiki.Resource  +
Has roleResearch forum portal  +
Idnlx_143806  +
Is part ofEmory University; Georgia; USA  +
KeywordsTraumatic brain injury  +, Progesterone  +, Clinical trial  +, Neuroprotection  +, and One Mind TBI  +
LabelResource:ProTECT  +
ModifiedDate5 December 2011  +
PMID22033509, 17011666  +
Page has default formThis property is a special property in this wiki.Resource  +
SuperCategoryResource  +
Supporting AgencyNIH  +
SynonymProTECT III - Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment: Phase III Clinical Trial  +